(Q37660904)

21 August 2017

1 reference

title

The role of SRC-3 in human breast cancer (English)

1 reference

21 August 2017

1 reference

Ondrej Gojis

1

1 reference

21 August 2017

Bharath Rudraraju

2

1 reference

21 August 2017

Mihir Gudi

3

1 reference

21 August 2017

Katy Hogben

4

1 reference

21 August 2017

Sami Sousha

5

1 reference

21 August 2017

R Charles Coombes

6

1 reference

21 August 2017

Susan Cleator

7

1 reference

21 August 2017

Carlo Palmieri

8

1 reference

21 August 2017

language of work or name

English

0 references

publication date

22 December 2009

1 reference

Nature Reviews Clinical Oncology

21 August 2017

published in

1 reference

21 August 2017

volume

7

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

83-89

1 reference

Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

The nuclear receptor superfamily: the second decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Molecular mechanisms of action of steroid/thyroid receptor superfamily members

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Minireview: nuclear receptor coactivators--an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Review of the in vivo functions of the p160 steroid receptor coactivator family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Functional interaction between the p160 coactivator proteins and the transcriptional enhancer factor family of transcription factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Essential phosphatases and a phospho-degron are critical for regulation of SRC-3/AIB1 coactivator function and turnover

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

The coactivator LXXLL nuclear receptor recognition motif.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

The transcriptional coactivators p300 and CBP are histone acetyltransferases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Requirement for multiple domains of the protein arginine methyltransferase CARM1 in its transcriptional coactivator function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Steroid receptor coactivator-1 is a histone acetyltransferase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Transcriptional regulation by steroid receptor coactivator phosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Regulation of somatic growth by the p160 coactivator p/CIP

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Somatic instability of the DNA sequences encoding the polymorphic polyglutamine tract of the AIB1 gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

The role of coactivators in steroid hormone action.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Polyglutamine repeat length in theAIB1 gene modifies breast cancer susceptibility inBRCA1 carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Breast cancer risk inBRCA1 andBRCA2 mutation carriers and polyglutamine repeat length in theAIB1 gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Polymorphic repeat in AIB1 does not alter breast cancer risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Correlates of obesity in postmenopausal women with breast cancer: comparison of genetic, demographic, disease-related, life history and dietary factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Adiposity as a risk determinant for postmenopausal breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Body size and breast cancer prognosis: a critical review of the evidence.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Clinical Significance of AIB1 Expression in Human Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Expression of Sex Steroid Receptors and their Co-Factors in Normal and Malignant Breast Tissue: AIB1 is a Carcinoma-Specific Co-Activator

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Amplified in breast cancer 1 expression in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Automated subcellular localization and quantification of protein expression in tissue microarrays.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Proto-oncogene ACTR/AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Regulation of invasive cell behavior by taiman, a Drosophila protein related to AIB1, a steroid receptor coactivator amplified in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Quality of health care delivered to adults in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.219

Hybrid selection of transcribed sequences from microdissected DNA: isolation of genes within amplified region at 20q11-q13.2 in breast cancer

31 March 2020

1 reference

12 December 2020

Altered expression of estrogen receptor coregulators during human breast tumorigenesis

1 reference

12 December 2020

Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer

1 reference

12 December 2020

Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history.

1 reference

12 December 2020

Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer

1 reference

12 December 2020

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

12 December 2020

In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity

1 reference

12 December 2020

The steroid receptor coactivator, GRIP-1, is necessary for MEF-2C-dependent gene expression and skeletal muscle differentiation.

1 reference

12 December 2020

Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu.

1 reference

12 December 2020

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

12 December 2020

10.1038/NRCLINONC.2009.219

Identifiers

DOI

1 reference

21 August 2017

1 reference